Navigation Links
Pharmacyclics Reports Results for Six and Three Months Ended December 31, 2012
Date:2/14/2013

is open and Janssen plans to enroll 110 patients worldwide.
  • Phase Ib/II dose escalating study of ibrutinib in combination with R-CHOP in patients with newly diagnosed CD20 positive non-Hodgkin's lymphoma. The purpose of this study is to identify a safe and tolerable dose of ibrutinib in combination with R-CHOP, once a safe dose is established the study will expand and report responses of this combination in patients with newly diagnosed DLBCL. This global, multi-center study, conducted by Janssen, is open and Janssen plans to enroll 33 patients.
  • Phase II study of ibrutinib in subjects with relapsed or refractory multiple myeloma (MM): This is a Phase II, multi-center, open-label trial designed trial to assess the safety and efficacy of ibrutinib single agent and in combination with dexamethasone in subjects with relapsed or relapsed MM. This study is conducted by Pharmacyclics and is currently exploring ibrutinib administration at 560 mg in combination with dexamethasone. Two further cohorts are planned to be explored; 840 mg with dexamethasone and 840 mg as a single agent. The Company anticipates an update on this study will be provided by year end 2013.
  • Phase II open-label, multicenter, single-arm study of monotherapy ibrutinib in subjects with relapsed or refractory follicular lymphoma. The primary endpoint of this study is objective response rate. Janssen plans to enroll 110 patients in this study.
  • PCYC has received Orphan Drug and Fast Track designation for ibrutinib treatment of chronic lymphocytic leukemia last year. The FDA has also granted Orphan Drug and Fast Track designation most recently to ibrutinib for the treatment of mantle cell lymphoma.  A US orphan drug designation provides the drug developer with several benefits and incentives related to the orphan drug, including a 7-year period of U.S. marketing exclusivity if the drug is the first of its type approved for the specified indication. Fast tra
    '/>"/>

    SOURCE Pharmacyclics, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

    Related biology technology :

    1. Pharmacyclics Reports Fiscal 2013 First Quarter Financial Results and Multiple PCI-32765 Presentations at the 54th American Society of Hematology Annual Meeting
    2. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
    3. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
    4. Interleukin Genetics Reports Third Quarter 2011 Financial Results
    5. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
    6. Nile Therapeutics Reports 2011 Third Quarter Financial Results
    7. Pharmasset Reports Fiscal Year End 2011 Financial Results
    8. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
    9. SeraCare Reports Fiscal Year 2011 and Fourth Quarter Financial Results
    10. WaferGen Reports Third Quarter 2011 Financial Results and Announces New Commercialization Strategy
    11. Hadasit Bio-Holdings Ltd. Reports Significant External Financing for Portfolio Companies
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/29/2014)... -- Pfenex Inc. (NYSE MKT: PFNX), a clinical-stage biotechnology ... difficult to manufacture proteins including biosimilar therapeutics, today ... for the second quarter ended June 30, 2014. ... initial public offering, we have the capital to ... from our proprietary protein expression platform," stated Bertrand ...
    (Date:8/29/2014)... (PRWEB) August 29, 2014 Pittcon is ... MacDonald, and colleague Koichiro Matsuda, Horiba Scientific, have organized ... September 5, 2014. JASIS , Asia’s largest analytical ... 2014, in Makuhari Messe, Japan. , The four ... for Bioanalysis from Single Molecules to Single Cells” will ...
    (Date:8/29/2014)... August 29, 2014 Due to a misstatement ... week, the Adult Stem Cell Technology Center, LLC ( ASCTC ... stem cell therapy research that might benefit ALS patients. ... for new stem cell technologies and therapeutic applications, FRC listed ... Bucket Challenge donors who wish not to support research ...
    (Date:8/28/2014)... CA (PRWEB) August 28, 2014 Best ... products for the food processing industry, is asking industry ... side-by side comparison of the E2 soap they’re currently ... Sanitizing Foam Soap . Hand hygiene is critical ... the food processing environment. Six key criteria are identified ...
    Breaking Biology Technology:Pfenex Reports Second Quarter 2014 Results and Provides Business Update 2Pfenex Reports Second Quarter 2014 Results and Provides Business Update 3Pfenex Reports Second Quarter 2014 Results and Provides Business Update 4Pfenex Reports Second Quarter 2014 Results and Provides Business Update 5Pfenex Reports Second Quarter 2014 Results and Provides Business Update 6Pfenex Reports Second Quarter 2014 Results and Provides Business Update 7Pfenex Reports Second Quarter 2014 Results and Provides Business Update 8Fifth Annual U.S. Symposium at JASIS Organized by Pittcon’s Program Chairman Hub MacDonald 2The Adult Stem Cell Technology Center, LLC Declines ALS Ice Bucket Challenge Donors Wishing to Support Ethical Research for New Stem Cell Therapies 2The Adult Stem Cell Technology Center, LLC Declines ALS Ice Bucket Challenge Donors Wishing to Support Ethical Research for New Stem Cell Therapies 3Best Sanitizers, Inc. Asks Food Industry Professionals: With Fall Harvest On the Way, Is Your E2 Hand Soap Up to the Task? 2
    ... No longer must you endure the high cost , ... siRNA. The new Silencer siRNA Construction Kit , ... , your capacity for large siRNA screening experiments. ... same gene can be screened for a fraction of the , ...
    ... Mediating RNA interference (RNAi) with , ... been described in the literature (1). Recombinant adenoviruses ... other methods of nucleic acid , ... non-dividing cells, and can be used in animal model systems. , ...
    ... For Long Term Studies in Mammalian Cells , ... vectors are now available, each with an antibiotic resistance ... selection in mammalian cultured cells. , ... specific knockdown. Gene specific silencing in mammilian cells , ...
    Cached Biology Technology:Test More siRNAs for Less 2Test More siRNAs for Less 3Superior Gene Silencing Using Adenoviral Vectors 2Superior Gene Silencing Using Adenoviral Vectors 3Superior Gene Silencing Using Adenoviral Vectors 4Superior Gene Silencing Using Adenoviral Vectors 5siRNA Expression Vectors with Selectable Markers 2siRNA Expression Vectors with Selectable Markers 3siRNA Expression Vectors with Selectable Markers 4siRNA Expression Vectors with Selectable Markers 5
    (Date:9/1/2014)... alteration of a single nucleotidethe basic building block of DNAcould initiate ... The study appears in The Journal of Cell Biology ... a defect in a gene on the X chromosome called ... women and 1 in 360 men carry a so-called premutation, in ... FMR1 gene is slightly longer than normal. These repeats ...
    (Date:8/31/2014)... at the University of Warwick have discovered that ,good, ... , The substance, methylglyoxal - MG, was found to ... bad cholesterol from the body. , Low levels ... heart disease, with increased levels of MG being common ... problems. , Supported by funding from the British ...
    (Date:8/31/2014)... When they are not busy attacking us, germs go ... doesn,t always spell disaster for the infected microbes: Sometimes ... harness to, say, expand its diet or better attack ... version of an immune system would robotically destroy anything ... at Rockefeller University have now revealed that one variety ...
    Breaking Biology News(10 mins):A nucleotide change could initiate fragile X syndrome 2Sugar substance 'kills' good HDL cholesterol, new research finds 2Discovery reveals how bacteria distinguish harmful vs. helpful viruses 2Discovery reveals how bacteria distinguish harmful vs. helpful viruses 3
    ... University of Illinois at Urbana-Champaign has received a fiveyear, $5.7 ... in corn. These strains have the potential to combat the ... yield. A team at the Institute for Genomic Biology in ... lead the research. "Ozone can cause major damage ...
    ... first bulb, heat has been a mostly undesirable byproduct of ... heat at the point of need, on the nanoscale, to ... created by the Rice labs of Michael Wong, Ramon Gonzalez ... Society journal ACS Nano makes use of materials ...
    ... evades detection and establishes a stronghold without setting off ... this week help explain how the stealthy agent of Black ... The authors of the study, appearing in the Dec. ... Dr. Christopher N. LaRock of the University of Washington Department ...
    Cached Biology News:University of Illinois receives grant to study ozone resistance in corn 2Rice uses light to remotely trigger biochemical reactions 2Rice uses light to remotely trigger biochemical reactions 3Rice uses light to remotely trigger biochemical reactions 4Dark Ages scourge enlightens modern struggle between man and microbes 2Dark Ages scourge enlightens modern struggle between man and microbes 3
    ... (MUC3) is a glycoprotein. distributed in ... extent in breast, lung and salivary gland ... cross-reaction with MUC1 and MUC2. ... Immunogen: MUC3 tandem repeat peptide ...
    ... bottoms,• Nonreversible lids with ... contamination,• Individual alphanumerical codes ... footprint for ease in ... cell attachment,• Sterilized by ...
    Rabbit polyclonal to GABA A Receptor gamma 2 ( Abpromise for all tested applications). entrezGeneID: 2566 SwissProtID: P18507...
    Rabbit polyclonal to VPAC2 ( Abpromise for all tested applications). entrezGeneID: 7434 SwissProtID: P41587...
    Biology Products: